Takeda's Dengue Vaccine Candidate Aims To Avoid Dengvaxia Problems
TAK-003 is designed to be effective in those never exposed to dengue; Takeda expects Phase III results by end of 2018.
TAK-003 is designed to be effective in those never exposed to dengue; Takeda expects Phase III results by end of 2018.